Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 52Neoplasm Metastasis 11Neoplasms 8Recurrence 7Prostate Cancer Metastatic 6Breast Neoplasms 5Carcinoma, Transitional Cell 4Stomach Neoplasms 3Neoplastic Cells, Circulating 3Metastatic Castration-resistant Prostate Cancer 3Carcinoma, Non-Small-Cell Lung 3Brain Neoplasms 3Urinary Bladder Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms, Castration-Resistant 2Ovarian Neoplasms 2Glioblastoma 2Carcinoma, Squamous Cell 2Thrombocytosis 1Testicular Neoplasms 1Solid Cancer 1Small Cell Lung Carcinoma 1Prostate Cancer, Hereditary, 7 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Penile Neoplasms 1Pancreatic Neoplasms 1Oligodendroglioma 1Nonseminomatous germ cell tumor 1Myeloproliferative Disorders 1

Interventions

enzalutamide 20Abiraterone Acetate 11Prednisone 7Docetaxel 7radium Ra 223 dichloride 6darolutamide 5abiraterone 5apalutamide 3olaparib 2niraparib 2cabazitaxel 2atezolizumab 2Pluvicto 2Nivolumab 2zimberelimab 1xentuzumab 1tasquinimod 1sacituzumab govitecan 1sabizabulin 1quemliclustat 1pembrolizumab 1ipatasertib 1ibrutinib 1gedatolisib 1gallium 68 PSMA-11 1fludrocortisone acetate 1TVB-2640 1Standard of Care 1Rosuvastatin Calcium 1Radium-223 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Prostatic Neoplasms, Castration-Resistant × cabazitaxel × Clear all
NCT06353386 2026-05-26

MK-5684-01A

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
220 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT02254785 2017-12-06

Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer

British Columbia Cancer Agency

Phase 2 Unknown
120 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡